Publication: Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesis.
Loading...
Identifiers
Publication date
Advisors
Journal Title
Journal ISSN
Volume Title
Publishers
Oxford University Press
Abstract
Obesity is characterized by low-grade inflammation, energy imbalance and impaired thermogenesis. The role of regulatory T cells (Treg) in inflammation-mediated maladaptive thermogenesis is not well established. Here, we find that the p38 pathway is a key regulator of T cell-mediated adipose tissue (AT) inflammation and browning. Mice with T cells specifically lacking the p38 activators MKK3/6 are protected against diet-induced obesity, leading to an improved metabolic profile, increased browning, and enhanced thermogenesis. We identify IL-35 as a driver of adipocyte thermogenic program through the ATF2/UCP1/FGF21 pathway. IL-35 limits CD8 T cell infiltration and inflammation in AT. Interestingly, we find that IL-35 levels are reduced in visceral fat from obese patients. Mechanistically, we demonstrate that p38 controls the expression of IL-35 in human and mouse Treg cells through mTOR pathway activation. Our findings highlight p38 signaling as a molecular orchestrator of AT T cell accumulation and function.
Description
IN was funded by EFSD/Lilly grants (2017 and 2019), the CNIC IPP FP7 Marie Curie Programme (PCOFUND-2012-600396), an EFSD Rising Star award (2019), and grant MINECO IJC2018-035390-I. IR FPI-MCIN PRE2020-092784. MC was an FPI-MINECO fellow (BES-2017–079711). RRB is a fellow of the FPU Program (FPU17/03847). ML was supported by Spanish grant MINECO-FEDER SAF2015-74112-JIN and Fundación AECC: INVES20026LEIV. ABP-G MG was awarded with FPI BES-2017 − 081381. JV was supported by MICIU/AEI/10.13039/501100011033 and by European Union (grants PID2021-122348NBI00, PLEC2022-009298, PLEC2022-009235 and EQC2021-007053-P), by the Comunidad de Madrid (S2022/BMD-7333-CM), and by “La Caixa” Foundation
(LCF/PR/HR22/52420019). MM has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI20/00743 and INT21/00065 to MM and cofunded by the European Union and by Junta de Castilla y León, Spain through projects GRS 2388/A/21 and GRS 2648/A/22 to MM. PM is supported by
MICIN-ISCIII-Fondo de Investigación Sanitaria (PI22/01759; PMPTA22/00090-BIOCARDIOTOX) and Comunidad de Madrid (P2022/BMD-7209-
INTEGRAMUNE-CM; Spain). GS is a EMBO YIP member, received funding from the following programs and organizations: MCIN PGC2018-097019-BI00; European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement ERC 260464; the EFSD/Lilly European Diabetes Research
Programme; Fundación AECC PROYE19047SABI; BBVA Foundation Leonardo Grants Program for Researchers and Cultural Creators (Investigadores-BBVA2017) IN[17]_BBM_BAS_0066; MINECO-FEDER SAF2016-79126-R and PID2019-104399RB-I00, MICIN-FEDER PID2022-138525OB-I00 2023-26; and
the Comunidad de Madrid (IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/BMD-3733), PMP21/00057. GS. MM, JV, JT has been awarded
with Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021 PMP21/00113. Instituto de Salud Carlos III.,
PDC2021-121147-I00.Convocatoria: Proyectos Prueba de Concepto 2021. Ministerio de Ciencia e Innovación. The CNIC is supported by the Instituto de
Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant
CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033).
MeSH Terms
DeCS Terms
Bibliographic citation
EMBO Rep. 2024 Jun;25(6):2635-2661.





